Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Thursday, July 28, 2011
Hepatitis B and C Prevalent in Injecting Drug Users
The investigators found that, based on eligible reports with anti-HCV prevalence data from IDUs in 77 counties, the midpoint anti-HCV prevalence was 60 to 80 percent in 25 countries and more than 80 percent in 12 countries; worldwide, there might be up to 10 million anti-HCV-positive IDUs, with the highest numbers in China, the United States, and Russia. Eligible HBsAg reports were identified for 59 countries, with midpoint prevalence of 5 to 10 percent in 21 countries and more than 10 percent in 10 countries. Overall, an estimated 6.4 million and 1.2 million IDUs were anti-HBc positive and HBsAg positive, respectively.